News about Global Pharma

Pacific Software Acquires 107 Canada from PurMinds

Pacific Software Inc. has acquired 10763942 Canada Inc. (107 Canada) and its PurMinds asset portfolio, strengthening its position in clinical-stage neuromedicine with a pipeline targeting neurological and psychiatric disorders.

Global Pharma | 27/08/2025 | By Mrinmoy Dey |  196

Clyra Medical Technologies Appoints David Zansitis as Vice President of Clinical Affairs

In this new role, David Zansitis will provide strategic clinical leadership, partnering with Clyra’s Chief Medical Officer to expand the company’s clinical roadmap.

Global Pharma | 27/08/2025 | By Dineshwori |  188

AbbVie to Acquire Gilgamesh's Psychedelic Antidepressant Bretisilocin in USD 1.2 Billion Deal

AbbVie has announced a USD 1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ lead candidate bretisilocin, a next-generation psychedelic compound in clinical development for treating moderate-to-severe major depressive disorder.

Global Pharma | 26/08/2025 | By Mrinmoy Dey |  256

Scenic Biotech Partners with Alnylam to Advance RNAi Therapeutics Using Cell-Seq Platform

This collaboration represents Scenic Biotech’s third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb. <br />

Global Pharma | 26/08/2025 | By Dineshwori |  335

Er-Kim Partners with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey

Istanbul-based Er-Kim, an international pharmaceutical company specialising in the commercialisation of novel therapies, has entered into a distribution agreement with UK-based CNX Therapeutics to supply selected oncology products across Central and Eastern Europe (CEE) and Turkey.

Global Pharma | 26/08/2025 | By Dineshwori |  419

Malaysia, Singapore Partner to Launch Medical Device Regulatory Reliance Pilot

The Medical Device Authority (MDA) of Malaysia and the Health Sciences Authority (HSA) of Singapore have signed a Memorandum of Understanding (MOU) to deepen regulatory cooperation and officially launched a 6-month pilot of the Medical Device Regulatory Reliance Programme.

Global Pharma | 26/08/2025 | By Dineshwori |  331

CuraTeQ Biologics Receives UK MHRA Approval for Trastuzumab Biosimilar Dazublys

CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys.

Global Pharma | 26/08/2025 | By Dineshwori |  652

MannKind to Acquire scPharmaceuticals, Expanding into Cardiorenal Medicine

MannKind’s acquisition of scPharmaceuticals is expected to be completed in the fourth quarter of 2025.

Global Pharma | 25/08/2025 | By Dineshwori |  312

GSK Enters Oncology in India with Launch of Jemperli and Zejula for Gynaecological Cancers

GSK has launched its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, reinforcing its commitment to addressing the unmet need for gynaecological cancers in the country.

Global Pharma | 25/08/2025 | By Dineshwori |  435

Bio-Thera, STADA Expand Biosimilars Alliance to Include Tocilizumab

Bio-Thera Solutions and STADA Arzneimittel have extended their biosimilars alliance to include tocilizumab, with Bio-Thera handling development and supply while STADA secures exclusive commercialization rights across Europe and select markets.

Global Pharma | 25/08/2025 | By Mrinmoy Dey |  319